• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

a-苯胺基酮、酯和酰胺：化学研究。

a-Anilinoketones, Esters and Amides: A Chemical Study.

机构信息

Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.

出版信息

Pharmaceuticals (Basel). 2012 Jun 5;5(6):591-612. doi: 10.3390/ph5060591.

DOI:10.3390/ph5060591
PMID:24281663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3763659/
Abstract

A group of a-anilinoketones, 2-aminoalcohols, a-anilinoesters and a-anilinoamides were successfully synthesized and characterized by NMR spectroscopy and mass spectrometry. The yields were, in general, moderate to good (up to 75.4%), except for the a-anilinoesters (16.9-35.6%). The a-halocarbonyl starting materials showed different chemical reactivities. a-Haloketones and a-chloroacetates afforded monoalkylation, while small a-chloroamides afforded dialkylation. Finally, NMR spectroscopy revealed interesting structural features about the 2-aminoalcohols and diphenylamides.

摘要

一组 a-苯胺酮、2-氨基醇、a-苯胺酯和 a-苯胺酰胺被成功地通过 NMR 光谱和质谱进行了合成和表征。除了 a-苯胺酯（16.9-35.6%）外，产率通常为中等至良好（高达 75.4%）。a-卤羰基起始材料表现出不同的化学反应性。a-卤酮和 a-氯乙酸酯得到单烷基化，而小的 a-氯酰胺得到二烷基化。最后，NMR 光谱揭示了 2-氨基醇和二苯胺酰胺的有趣结构特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/4c04bad60f2e/pharmaceuticals-05-00591-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/34d89e2f2ecb/pharmaceuticals-05-00591-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/04eeb88a72c1/pharmaceuticals-05-00591-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/bb3a22d3d7d5/pharmaceuticals-05-00591-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/d25e38db36f0/pharmaceuticals-05-00591-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/5d18ae6d7ec0/pharmaceuticals-05-00591-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/76aa65f46e4a/pharmaceuticals-05-00591-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/d23ee76f18cc/pharmaceuticals-05-00591-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/4b09ec487e1f/pharmaceuticals-05-00591-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/8e6485a1e5ed/pharmaceuticals-05-00591-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/0bfd011cd2d8/pharmaceuticals-05-00591-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/d74b91aa3b03/pharmaceuticals-05-00591-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/52b7869bbce1/pharmaceuticals-05-00591-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/4c04bad60f2e/pharmaceuticals-05-00591-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/34d89e2f2ecb/pharmaceuticals-05-00591-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/04eeb88a72c1/pharmaceuticals-05-00591-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/bb3a22d3d7d5/pharmaceuticals-05-00591-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/d25e38db36f0/pharmaceuticals-05-00591-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/5d18ae6d7ec0/pharmaceuticals-05-00591-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/76aa65f46e4a/pharmaceuticals-05-00591-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/d23ee76f18cc/pharmaceuticals-05-00591-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/4b09ec487e1f/pharmaceuticals-05-00591-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/8e6485a1e5ed/pharmaceuticals-05-00591-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/0bfd011cd2d8/pharmaceuticals-05-00591-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/d74b91aa3b03/pharmaceuticals-05-00591-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/52b7869bbce1/pharmaceuticals-05-00591-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96ac/3763659/4c04bad60f2e/pharmaceuticals-05-00591-g004.jpg

相似文献

1
a-Anilinoketones, Esters and Amides: A Chemical Study.a-苯胺基酮、酯和酰胺：化学研究。
Pharmaceuticals (Basel). 2012 Jun 5;5(6):591-612. doi: 10.3390/ph5060591.
2
Control of extremely fast competitive consecutive reactions using micromixing. Selective Friedel-Crafts aminoalkylation.利用微混合控制极快速竞争性连续反应。选择性傅克氨基烷基化反应。
J Am Chem Soc. 2005 Aug 24;127(33):11666-75. doi: 10.1021/ja0527424.
3
Efficient synthesis of 2-aminoindane-2-carboxylic acid via dialkylation of nucleophilic glycine equivalent.通过亲核甘氨酸等价物的二烷基化高效合成2-氨基茚满-2-羧酸
J Org Chem. 2003 Jun 13;68(12):4973-6. doi: 10.1021/jo030065v.
4
Synthesis of α,β-unsaturated α'-haloketones through the chemoselective addition of halomethyllithiums to Weinreb amides.通过选择性卤代甲基锂与 Weinreb 酰胺的加成反应合成α，β-不饱和α'-卤代酮。
J Org Chem. 2013 Aug 2;78(15):7764-70. doi: 10.1021/jo401236t. Epub 2013 Jul 16.
5
Traceless Staudinger ligation of glycosyl azides with triaryl phosphines: stereoselective synthesis of glycosyl amides.糖基叠氮化物与三芳基膦的无痕施陶丁格连接：糖基酰胺的立体选择性合成
J Org Chem. 2006 Jun 9;71(12):4565-77. doi: 10.1021/jo060409s.
6
Alpha-heteroarylation of esters, lactones, amides, and lactams by nucleophilic aromatic substitution.通过亲核芳香取代反应实现酯、内酯、酰胺和内酰胺的α-杂芳基化。
Org Lett. 2006 Mar 30;8(7):1447-50. doi: 10.1021/ol060246u.
7
Structural Criteria for the Rational Design of Selective Ligands. 2. Effect of Alkyl Substitution on Metal Ion Complex Stability with Ligands Bearing Ethylene-Bridged Ether Donors.选择性配体合理设计的结构标准。2. 烷基取代对带有乙烯桥连醚供体的配体与金属离子配合物稳定性的影响。
Inorg Chem. 1996 Apr 24;35(9):2650-2658. doi: 10.1021/ic9514760.
8
Reaction between drug substances and pharmaceutical excipients: formation of citric acid esters and amides of carvedilol in the solid state.药物物质与药用辅料之间的反应：固态下卡维地洛柠檬酸酯和酰胺的形成。
J Pharm Biomed Anal. 2009 Jan 15;49(1):11-7. doi: 10.1016/j.jpba.2008.09.039. Epub 2008 Oct 2.
9
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
J Med Chem. 1997 Feb 28;40(5):659-67. doi: 10.1021/jm960752x.
10
Synthesis of (E)-alpha-hydroxy-beta,gamma-unsaturated amides with high selectivity from alpha,beta-epoxyamides by using catalytic samarium diiodide or triiodide.使用催化量的二碘化钐或三碘化钐从α,β-环氧酰胺高选择性合成(E)-α-羟基-β,γ-不饱和酰胺。
Chemistry. 2004 May 17;10(10):2445-50. doi: 10.1002/chem.200305375.

引用本文的文献

1
Novel Aminopyrimidine-2,4-diones, 2-Thiopyrimidine-4-ones, and 6-Arylpteridines as Dual-Target Inhibitors of BRD4/PLK1: Design, Synthesis, Cytotoxicity, and Computational Studies.新型氨基嘧啶 -2,4- 二酮、2- 硫代嘧啶 -4- 酮和 6- 芳基蝶啶作为 BRD4/PLK1 的双靶点抑制剂：设计、合成、细胞毒性及计算研究
Pharmaceuticals (Basel). 2023 Sep 15;16(9):1303. doi: 10.3390/ph16091303.
2
Design, synthesis, and biological evaluation with molecular dynamics study of novel pyrazolo[3,4-]pyrimidine derivatives as anti-cancer agents.新型吡唑并[3,4 -]嘧啶衍生物作为抗癌剂的设计、合成及分子动力学研究的生物学评价
RSC Adv. 2023 Jun 7;13(25):17074-17096. doi: 10.1039/d3ra00446e. eCollection 2023 Jun 5.
3

本文引用的文献

1
Measurement of one-bond heteronuclear dipolar coupling contributions for amine and diastereotopic methylene protons.胺和非对映异位亚甲基质子的一键异核偶极耦合贡献的测量。
J Magn Reson. 2004 Jun;168(2):307-13. doi: 10.1016/j.jmr.2004.03.007.
2
3-(Arylacetylamino)-N-methylbenzamides: a novel class of selective anti-Helicobacter pylori agents.3-（芳基乙酰氨基）-N-甲基苯甲酰胺：一类新型的选择性抗幽门螺杆菌药物。
J Med Chem. 2001 Dec 6;44(25):4468-74. doi: 10.1021/jm010307o.
3
Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis.
Identification of a potent NAFLD drug candidate for controlling T2DM-mediated inflammation and secondary damage and .
鉴定一种有效的非酒精性脂肪性肝病候选药物，用于控制2型糖尿病介导的炎症和继发性损伤。
Front Pharmacol. 2022 Aug 19;13:943879. doi: 10.3389/fphar.2022.943879. eCollection 2022.
4
A metal-free approach for the synthesis of amides/esters with pyridinium salts of phenacyl bromides via oxidative C-C bond cleavage.一种通过氧化碳-碳键裂解，以苯甲酰溴吡啶盐合成酰胺/酯的无金属方法。
Beilstein J Org Chem. 2019 Aug 5;15:1864-1871. doi: 10.3762/bjoc.15.182. eCollection 2019.
幽门螺杆菌感染诱导的胃上皮细胞凋亡：对胃癌发生的影响。
Am J Gastroenterol. 2001 Jan;96(1):16-26. doi: 10.1111/j.1572-0241.2001.03447.x.
4
Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).多巴胺D3受体选择性激动剂(4aR,10bR)-(+)-反式-3,4,4a,10b-四氢-4-正丙基-2H,5H-[1]苯并吡喃并[4,3-b]-1,4-恶嗪-9-醇(PD 128907)的硫代吡喃类似物的合成及药理学评价
J Med Chem. 2000 Jul 27;43(15):2871-82. doi: 10.1021/jm0000113.
5
H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications.幽门螺杆菌与细胞毒素相关基因A：与胃癌、十二指肠溃疡、反流性食管炎及其并发症的关系。
Helicobacter. 1998 Sep;3(3):145-51. doi: 10.1046/j.1523-5378.1998.08031.x.
6
Association of virulent Helicobacter pylori strains with ischemic heart disease.致病性幽门螺杆菌菌株与缺血性心脏病的关联。
Circulation. 1998 May 5;97(17):1675-9. doi: 10.1161/01.cir.97.17.1675.
7
Helicobacter pylori.幽门螺杆菌
Infect Dis Clin North Am. 1998 Mar;12(1):185-97. doi: 10.1016/s0891-5520(05)70417-7.
8
Atopic dermatitis successfully treated by eradication of Helicobacter pylori.通过根除幽门螺杆菌成功治疗特应性皮炎。
J Gastroenterol. 1996 Nov;31 Suppl 9:77-82.
9
The prevalence of Helicobacter pylori in peptic ulcer disease.幽门螺杆菌在消化性溃疡疾病中的患病率。
Aliment Pharmacol Ther. 1995;9 Suppl 2:59-69.
10
Estimates of the worldwide incidence of eighteen major cancers in 1985.1985年全球18种主要癌症的发病率估计。
Int J Cancer. 1993 Jun 19;54(4):594-606. doi: 10.1002/ijc.2910540413.